Literature DB >> 10779772

IL-6 receptor independent stimulation of human gp130 by viral IL-6.

J Müllberg1, T Geib, T Jostock, S H Hoischen, P Vollmer, N Voltz, D Heinz, P R Galle, M Klouche, S Rose-John.   

Abstract

The genome of human herpes virus 8, which is associated with Kaposi's sarcoma, encodes proteins with similarities to cytokines and chemokines including a homologue of IL-6. Although the function of these viral proteins is unclear, they might have the potential to modulate the immune system. For viral IL-6 (vIL-6), it has been demonstrated that it stimulates IL-6-dependent cells, indicating that the IL-6R system is used. IL-6 binds to IL-6R, and the IL-6/IL-6R complex associates with gp130 which dimerizes and initiates intracellular signaling. Cells that only express gp130 but no IL-6R cannot be stimulated by IL-6 unless a soluble form of the IL-6R is present. This type of signaling has been shown for hematopoietic progenitor cells, endothelial cells, and smooth muscle cells. In this paper we show that purified recombinant vIL-6 binds to gp130 and stimulates primary human smooth muscle cells. IL-6R fails to bind vIL-6 and is not involved in its signaling. A Fc fusion protein of gp130 turned out to be a potent inhibitor of vIL-6. Our data demonstrate that vIL-6 is the first cytokine which directly binds and activates gp130. This property points to a possible role of this viral cytokine in the pathophysiology of human herpes virus 8.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779772     DOI: 10.4049/jimmunol.164.9.4672

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 3.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 4.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

5.  Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.

Authors:  H Li; H Wang; J Nicholas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.

Authors:  Marina Kovaleva; Ingo Bussmeyer; Björn Rabe; Joachim Grötzinger; Enge Sudarman; Jutta Eichler; Udo Conrad; Stefan Rose-John; Jürgen Scheller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 7.  Interleukin-6 Family Cytokines.

Authors:  Stefan Rose-John
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-02-01       Impact factor: 10.005

Review 8.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 9.  HIV-associated multicentric Castleman disease.

Authors:  Deepa Reddy; Ronald Mitsuyasu
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

10.  The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR).

Authors:  Eva-Maria Wagener; Matthias Aurich; Samadhi Aparicio-Siegmund; Doreen M Floss; Christoph Garbers; Kati Breusing; Björn Rabe; Ralf Schwanbeck; Joachim Grötzinger; Stefan Rose-John; Jürgen Scheller
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.